BR0008403A - Formulação farmacêutica para administração oral - Google Patents

Formulação farmacêutica para administração oral

Info

Publication number
BR0008403A
BR0008403A BR0008403-4A BR0008403A BR0008403A BR 0008403 A BR0008403 A BR 0008403A BR 0008403 A BR0008403 A BR 0008403A BR 0008403 A BR0008403 A BR 0008403A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
oral administration
proton pump
pump inhibitor
oral
Prior art date
Application number
BR0008403-4A
Other languages
English (en)
Inventor
Keith Freehauf
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BR0008403A publication Critical patent/BR0008403A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"FORMULAçãO FARMACêUTICA PARA ADMINISTRAçãO ORAL". A presente invenção refere-se a uma formulação farmacêutica oral contendo um inibidor de bomba de prótons (PPI) que é adequada para tratamento de doenças relacionadas a ácido gástrico no homem e nos animais. Mais especificamente, a composição é uma pasta e é particularmente adequada para administrar um inibidor de bomba de prótons a cavalos.
BR0008403-4A 1999-02-23 2000-02-18 Formulação farmacêutica para administração oral BR0008403A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12125399P 1999-02-23 1999-02-23
PCT/US2000/004170 WO2000050038A1 (en) 1999-02-23 2000-02-18 Pharmaceutical composition containing proton pump inhibitors

Publications (1)

Publication Number Publication Date
BR0008403A true BR0008403A (pt) 2002-01-29

Family

ID=22395498

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008403-4A BR0008403A (pt) 1999-02-23 2000-02-18 Formulação farmacêutica para administração oral

Country Status (31)

Country Link
US (1) US6316481B1 (pt)
EP (1) EP1156806B1 (pt)
JP (1) JP2002537337A (pt)
KR (1) KR100701448B1 (pt)
CN (1) CN1227009C (pt)
AR (1) AR029615A1 (pt)
AT (1) ATE263562T1 (pt)
AU (1) AU771061B2 (pt)
BG (1) BG65291B1 (pt)
BR (1) BR0008403A (pt)
CA (1) CA2362932C (pt)
CO (1) CO5140102A1 (pt)
CZ (1) CZ301647B6 (pt)
DE (1) DE60009675T2 (pt)
DK (1) DK1156806T3 (pt)
EA (1) EA004683B1 (pt)
ES (1) ES2216870T3 (pt)
HK (1) HK1041650A1 (pt)
HR (1) HRP20010615B1 (pt)
HU (1) HU228181B1 (pt)
IL (1) IL144131A0 (pt)
ME (1) ME00864B (pt)
NO (1) NO328863B1 (pt)
NZ (1) NZ512771A (pt)
PL (1) PL195783B1 (pt)
PT (1) PT1156806E (pt)
RS (1) RS50023B (pt)
SK (1) SK286371B6 (pt)
TW (1) TW587936B (pt)
WO (1) WO2000050038A1 (pt)
ZA (1) ZA200106104B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
ES2345873T3 (es) 2000-05-30 2010-10-05 Merial Limited Composiciones para la prevencion de ulceras en caballos.
CN100528232C (zh) 2000-12-07 2009-08-19 尼科梅德有限责任公司 包含酸不稳定活性成分的混悬液形式的药物制剂
DE10061135C1 (de) * 2000-12-07 2002-11-07 Byk Gulden Lomberg Chem Fab Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff
CN100536844C (zh) 2000-12-07 2009-09-09 尼科梅德有限责任公司 包含酸不稳定活性成分的糊剂形式的药物制剂
EP1534278A4 (en) 2002-08-01 2006-09-06 Nitromed Inc NITROSED PROTONATE PUMP INHIBITORS, COMPOSITIONS AND USE METHOD
GB2394895A (en) * 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
WO2005000269A1 (en) * 2003-06-26 2005-01-06 Cipla Limited Pharmaceutical formulations comprising a proton pump inhibitor
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006026829A1 (en) * 2004-09-09 2006-03-16 Metelli Pty Ltd Stable paste composition of enteric coated acid labile active agent and use thereof
CN101500553B (zh) * 2006-07-25 2012-04-18 维克塔有限公司 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法
JP4588791B2 (ja) * 2007-02-16 2010-12-01 あすか製薬株式会社 微粒子油性懸濁液を含む医薬組成物
JP2012533633A (ja) * 2009-07-20 2012-12-27 ベテゲン・エルエルシー 経口投与のための安定な薬学的オメプラゾール製剤
WO2012106058A2 (en) 2011-01-31 2012-08-09 New Market Pharmaceuticals Animal treatments
US10064849B2 (en) 2012-05-02 2018-09-04 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
EP3505159B1 (en) * 2012-05-02 2020-11-04 NewMarket Pharmaceuticals LLC Pharmaceutical compositions for direct systemic introduction
WO2015055974A1 (en) * 2013-10-18 2015-04-23 Norbrook Laboratories Limited Proton pump inhibitor paste compositions
GB2524351B (en) * 2013-10-18 2016-12-14 Norbrook Lab Ltd Proton Pump Inhibitor Paste Compositions
BR112018011552A2 (pt) 2015-12-08 2018-11-27 Luoda Pharma Pty Ltd métodos e composições para tratamento de úlceras gástricas
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3033065A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
EP3720844A4 (en) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation MEDICINAL COMPOSITIONS
ES2723873B1 (es) * 2018-03-01 2020-05-13 Hernan Ma Carmen Batanero Medicamento combinado con omeprazol y vitamina B12
CN112972481A (zh) * 2021-03-18 2021-06-18 华农（肇庆）生物产业技术研究院有限公司 药物组合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255432A (en) 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
DK130287D0 (da) 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors

Also Published As

Publication number Publication date
AR029615A1 (es) 2003-07-10
NZ512771A (en) 2003-02-28
CA2362932A1 (en) 2000-08-31
CO5140102A1 (es) 2002-03-22
EP1156806B1 (en) 2004-04-07
US6316481B1 (en) 2001-11-13
TW587936B (en) 2004-05-21
HUP0200325A3 (en) 2003-05-28
ES2216870T3 (es) 2004-11-01
EA200100905A1 (ru) 2002-02-28
KR20010102297A (ko) 2001-11-15
CN1341022A (zh) 2002-03-20
CZ301647B6 (cs) 2010-05-12
JP2002537337A (ja) 2002-11-05
PT1156806E (pt) 2004-07-30
CA2362932C (en) 2010-11-30
PL195783B1 (pl) 2007-10-31
NO20014074D0 (no) 2001-08-22
HUP0200325A2 (en) 2002-06-29
HK1041650A1 (en) 2002-07-19
KR100701448B1 (ko) 2007-03-30
ATE263562T1 (de) 2004-04-15
ME00864B (me) 2008-09-29
IL144131A0 (en) 2002-05-23
DK1156806T3 (da) 2004-08-02
EP1156806A1 (en) 2001-11-28
DE60009675D1 (de) 2004-05-13
NO20014074L (no) 2001-08-22
CZ20013058A3 (cs) 2001-11-14
BG65291B1 (bg) 2007-12-28
CN1227009C (zh) 2005-11-16
HRP20010615A2 (en) 2002-12-31
BG105754A (en) 2002-03-29
ZA200106104B (en) 2002-12-24
AU771061B2 (en) 2004-03-11
DE60009675T2 (de) 2005-03-24
AU3368700A (en) 2000-09-14
YU50401A (sh) 2004-05-12
SK286371B6 (sk) 2008-08-05
EA004683B1 (ru) 2004-06-24
HU228181B1 (en) 2013-01-28
RS50023B (sr) 2008-09-29
HRP20010615B1 (en) 2011-03-31
WO2000050038A1 (en) 2000-08-31
NO328863B1 (no) 2010-05-31
PL350729A1 (en) 2003-01-27
SK12062001A3 (sk) 2001-12-03

Similar Documents

Publication Publication Date Title
BR0008403A (pt) Formulação farmacêutica para administração oral
BR9604803A (pt) Composição farmacêutica para administração oral
FI955124A (fi) Protonipumppuinhibiittorin sisältävä eläinlääkeseos
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
TR200101633T2 (tr) Farmasötik bileşim
KR970025615A (ko) 암 전이 억제제
BRPI0410131A (pt) suplemento dietético para uso no tratamento e/ou inibição de úlceras do trato digestivo em equinos e outros animais e seu método
MC2142A1 (fr) Medicament contre la toxoplasmose
PT975581E (pt) Composicoes solidas adequadas para administracao oral compreendendo tartarato de l-carnitina e colina ou de alcanoil-l-carnitina e colina
MC2203A1 (fr) Medicament contre la cryptosporidiose
BR0207299A (pt) Composição farmacêutica, solução aquosa e métodos para fabricar e para preparar uma composição, para instruir um humano a ingerir uma composição farmacêutica de liberação imediata e para tratar um humano
BR0002260A (pt) Métodos e composições para o tratamento de distúrbios relacionados com a idade, em animais de companhia
RU94011850A (ru) Применение диакватрихлоркупират метилметионинсульфония в качестве стимулятора биосинтетической функции печени

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SHARP AND DOHME CORP. (US)

Free format text: NOME ALTERADO DE: MERCK AND CO., INC.